ArticleInternational journal of clinical and experimental pathology2014
MAGE-A3 is highly expressed in a cancer stem cell-like side population of bladder cancer cells.
Article in International journal of clinical and experimental pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 39 citations in OpenAlex.
- Bladder cancer biomarkers: current approaches and future directions.Frontiers in oncology · 2024Review
- Tissue-specific cancer stem/progenitor cells: Therapeutic implications.World journal of stem cells · 2023Review
- CD24: A Marker for an Extended Expansion Potential of Urothelial Cancer Cell Organoids In Vitro?International journal of molecular sciences · 2022Article
- When Onco-Immunotherapy Meets Cold Atmospheric Plasma: Implications on CAR-T Therapies.Frontiers in oncology · 2022Review
- Repurposing of Anticancer Stem Cell Drugs in Brain Tumors.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2021Review
- Pathogenicity of the MAGE family.Oncology letters · 2021Review
- Randomized phase II trial of a first-in-human cancer cell lysate vaccine in patients with thoracic malignancies.Translational lung cancer research · 2021Article
- YBX2 and cancer testis antigen 45 contribute to stemness, chemoresistance and a high degree of malignancy in human endometrial cancer.Scientific reports · 2021Article
- Emerging roles of the MAGE protein family in stress response pathways.The Journal of biological chemistry · 2020Review
- Magnesium in Combinatorial With Valproic Acid Suppressed the Proliferation and Migration of Human Bladder Cancer Cells.Frontiers in oncology · 2020Article
- Expression dynamics ofOncotarget · 2019Article
- Melanoma-associated antigen-A and programmed death-ligand 1 expression are associated with advanced urothelial carcinoma.Cancer immunology, immunotherapy : CII · 2019Article
- Cancer/testis Antigen MAGEA3 Interacts with STAT1 and Remodels the Tumor Microenvironment.International journal of medical sciences · 2018Article
- Inhibition of Hes1 enhances lapatinib sensitivity in gastric cancer sphere-forming cells.Oncology letters · 2017Article
- Targeting the epigenome in malignant pleural mesothelioma.Translational lung cancer research · 2017Review
- DDX53 Regulates Cancer Stem Cell-Like Properties by Binding to SOX-2.Molecules and cells · 2017Article
- A Comprehensive Guide to the MAGE Family of Ubiquitin Ligases.Journal of molecular biology · 2017Review
- The cancer/testis antigen MAGEC2 promotes amoeboid invasion of tumor cells by enhancing STAT3 signaling.Oncogene · 2017Article
- MAGE expression in head and neck squamous cell carcinoma primary tumors, lymph node metastases and respective recurrences-implications for immunotherapy.Oncotarget · 2017Article
- DDX53 Promotes Cancer Stem Cell-Like Properties and Autophagy.Molecules and cells · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer stem cells (CSCs), which have the abilities of tumor-initiating, self-renewal and differentiation, are thought to cause post-therapeutic recurrence and the progression of cancer. However, CSCs are commonly resistant to current cancer therapies including chemotherapy and radiotherapy. In this study, we isolated cancer stem celllike side population (SP) cells from human bladder cancer cell line SW780 by a flow cytometry-based SP technique. SP cells were only about 3.6% of SW780 cells and showed higher expression of ATP-binding cassette sub-family G member 2 (ABCG2) and CD133. In vitro assay of tumor sphere growth as well as in vivo assay of xenograft transplantation confirmed the higher tumorigenicity of isolated SP cells. These data indicated that SP cells were enriched with CSCs of bladder cancer. Furthermore, we determined the expression of melanoma antigen family A, 3 (MAGEA3), one of the most studied cancer testis (CT) antigens, in these SP and main population (MP) cells derived from SW780 cells. SW780 SP cells representing CSCs of bladder cancer showed an up-regulated expression of MAGE-A3 and a positive coexpression of MAGE-A3 and CD133, indicating that MAGE-A3 was a novel CT antigen preferentially expressed in the CSCs of bladder cancer. In summary, our findings confirmed the existence of cancer stem cell-like SP cells in bladder cancer cells, and further indicated that MAGE-A3 is a novel CSC antigen and therefore may serve as an immunotherapeutic target for CSCs of bladder cancer.
Indexed as
Identifiers
25031712PMC4097252W2299905783What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.